首頁 > 市場調查報告書 > 食物/飲料

食品添加劑

市場調查報告書

商品編碼

1532561

解毒劑市場 - 按類型、給藥途徑、應用、最終用途 - 全球預測

Antidote Market - By Type, Route of Administration, Application, End-use - Global Forecast

出版日期: 2024年05月23日 | 出版商:

Global Market Insights Inc. | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在該領域不斷發展的研究和開發的推動下，2024年至2032年間，全球解毒劑市場的複合年成長率將達到8.1%。這種激增主要歸因於中毒案件發生率的增加以及人們對化學、生物、放射性和核（CBRN）威脅的認知不斷增強。醫學研究的進步導致更有效的解毒劑的發現，提高了它們的可用性和可及性。製藥公司正在大力投資研發，以開發新型解毒劑並改進現有解毒劑，以解決廣泛的毒素和毒物。例如，2024 年 7 月，來自雪梨和利物浦的研究人員在一篇詳細介紹多項突破的科學論文中發現，一種廣泛使用的血液稀釋劑也可以作為眼鏡蛇毒液的解毒劑。

此外，政府旨在加強國家對潛在化學和生物攻擊的準備的舉措刺激了市場成長。監管機構也正在加快新解毒劑的核准流程，確保更快進入市場。因此，在技術進步、研發活動增加以及中毒風險及其管理意識提高的推動下，全球解毒劑市場可望大幅擴張。

整個解毒劑產業根據類型、給藥途徑、應用、最終用途和地區進行分類。

根據類型，物理解毒劑市場收入從2024年到2032年將實現令人稱讚的複合年成長率。這些解毒劑在緊急情況下至關重要，可以提供快速介入並改善患者的治療結果。意外中毒和藥物過量的增加增加了對可用且有效的解毒劑解決方案的需求。此外，在開發新的物理解毒劑方面正在進行的研究和創新正在擴大其應用和有效性。因此，由於物理解毒劑在急診醫學中的關鍵作用，全球對物理解毒劑的需求預計將顯著成長。

就給藥途徑而言，從2024年到2032年，口服解毒劑將出現顯著成長。家庭使用。它們易於管理，在緊急情況下尤其有利，及時介入至關重要。藥物製劑的最新進展提高了口服解毒劑的功效和穩定性，增強了其治療潛力。隨著意外中毒發生率的增加以及對現成治療方案的需求，對口服解毒劑的需求可能會大幅增加，從而推動市場成長。

2024年至2032年，歐洲解毒劑市場將呈現顯著的複合年成長率。歐洲嚴格的監管環境確保了解毒劑功效和安全性的高標準，進一步推動了市場成長。此外，蛇咬傷、化學物質接觸和藥物過量的普遍存在需要現成的解毒劑溶液。歐洲製藥公司和研究機構之間的合作也正在促進創新，促進先進解毒劑配方的開發並推動市場需求。

產業生態系統分析
產業影響力
- 成長動力
  - 中毒和用藥過量的發生率增加
  - 提高意識和培訓計劃
  - 技術進步
  - 增加研究和開發活動
- 產業陷阱與挑戰
  - 不良反應和安全問題
  - 解毒劑研發及生產成本高
成長潛力分析
技術景觀
監管環境
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
競爭定位矩陣
戰略展望矩陣

第 5 章：市場估計與預測：按類型，2021 - 2032

主要趨勢
化學解毒劑
物理解毒劑
藥理解毒劑

第 6 章：市場估計與預測：按管理途徑，2021 年至 2032 年

主要趨勢
可注射
口服
專題

第 7 章：市場估計與預測：按應用分類，2021 - 2032

主要趨勢
藥物過量
化學中毒
食物中毒
其他應用

第 8 章：市場估計與預測：按最終用途，2021 - 2032 年

主要趨勢
醫院
診所
家庭護理設置
其他最終用戶

第 9 章：市場估計與預測：按地區分類，2021 - 2032 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 沙烏地阿拉伯
- 南非
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 10 章：公司簡介

Alvogen
Aurobindo Pharma Limited
Akorn Operating Company LLC
Baxter International, Inc.
Daiichi Sanko Group
Dr. Reddy's Laboratories Ltd.
Endo International plc
Emergent Biosolutions Inc.
Fresenius SE & Co. KGaA
Hikma Pharmaceuticals PLC
Nichi-Iko Pharmaceutical Co., Ltd.
Novartis AG
Pfizer Inc.
Viatris Inc.
Zydus Lifesciences Ltd.

簡介目錄

Product Code: 9616

Global Antidote Market will witness 8.1% CAGR between 2024 and 2032, driven by rising research and developments in the field. This surge is largely attributed to the increasing incidence of poisoning cases and the growing awareness of chemical, biological, radiological, and nuclear (CBRN) threats. Advances in medical research have led to the discovery of more effective antidotes, enhancing their availability and accessibility. Pharmaceutical companies are investing heavily in R&D to develop novel antidotes and improve existing ones, addressing a broad spectrum of toxins and poisons. For instance, in July 2024, in a scientific paper detailing multiple breakthroughs, researchers from Sydney and Liverpool discovered that a widely available blood thinner also functions as an antidote to cobra venom.

Furthermore, government initiatives aimed at bolstering national preparedness for potential chemical and biological attacks have spurred market growth. Regulatory agencies are also fast-tracking the approval processes for new antidotes, ensuring quicker market entry. As a result, the global antidote market is poised for substantial expansion, driven by technological advancements, increased R&D activities, and heightened awareness of poisoning risks and their management.

The overall Antidote Industry is classified based on the type, route of administration, application, end-use, and region.

Based on type, the antidote market revenue from the physical antidote segment will register a commendable CAGR from 2024 to 2032. Physical antidotes, such as activated charcoal and intravenous lipid emulsions, offer immediate and effective treatments for various poisonings and overdoses. These antidotes are essential in emergency settings, providing rapid intervention and improving patient outcomes. The rise in accidental poisonings and drug overdoses has heightened the need for accessible and efficient antidote solutions. Additionally, ongoing research and innovation in the development of new physical antidotes are expanding their applications and effectiveness. As a result, the global demand for physical antidotes is poised for significant growth, driven by their critical role in emergency medicine.

In terms of route of administration, the oral segment will witness an appreciable growth from 2024 to 2032. Oral antidotes offer a convenient, non-invasive option for treating poisonings and overdoses, making them accessible for both clinical and at-home use. Their ease of administration is particularly advantageous in emergencies, where timely intervention is crucial. Recent advancements in pharmaceutical formulations have improved the efficacy and stability of oral antidotes, enhancing their therapeutic potential. With the increasing incidence of accidental poisonings and the need for readily available treatment options, the demand for oral antidotes could rise significantly, driving market growth.

Europe antidote market will exhibit a notable CAGR from 2024 to 2032. With a growing focus on public health and safety, European countries are investing in the development and stockpiling of antidotes. The stringent regulatory environment in Europe ensures high standards for antidote efficacy and safety, further boosting market growth. Additionally, the prevalence of snakebites, chemical exposures, and drug overdoses necessitates readily available antidote solutions. The collaboration between European pharmaceutical companies and research institutions is also fostering innovation, leading to the development of advanced antidote formulations and driving market demand.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing incidence of poisoning and overdoses
  - 3.2.1.2 Growing awareness and training programs
  - 3.2.1.3 Technological advancements
  - 3.2.1.4 Increasing research and development activities
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Adverse effects and safety concerns
  - 3.2.2.2 High cost of antidote development and production
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Chemical antidote
5.3 Physical antidote
5.4 Pharmacological antidote

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Injectable
6.3 Oral
6.4 Topical

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Drug overdose
7.3 Chemical poisoning
7.4 Food poisoning
7.5 Other applications

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospitals
8.3 Clinics
8.4 Home care settings
8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 Saudi Arabia
- 9.6.2 South Africa
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa